Effects of herbal medicines (Eunkyosan/Yin qiao san and Samsoeum/Shen su yin) for treating the common cold: A randomized, placebo-controlled, multicenter clinical trial

IF 2.8 4区 医学 Q2 INTEGRATIVE & COMPLEMENTARY MEDICINE Integrative Medicine Research Pub Date : 2023-10-26 DOI:10.1016/j.imr.2023.101005
Kwan-Il Kim , Minna Hong , Yang-Chun Park , Beom-Joon Lee , Kitae Kim , Byoung Kab Kang , Jun-Yong Choi
{"title":"Effects of herbal medicines (Eunkyosan/Yin qiao san and Samsoeum/Shen su yin) for treating the common cold: A randomized, placebo-controlled, multicenter clinical trial","authors":"Kwan-Il Kim ,&nbsp;Minna Hong ,&nbsp;Yang-Chun Park ,&nbsp;Beom-Joon Lee ,&nbsp;Kitae Kim ,&nbsp;Byoung Kab Kang ,&nbsp;Jun-Yong Choi","doi":"10.1016/j.imr.2023.101005","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p><em>Eunkyosan</em> (EKS) and <em>Samsoeum</em> (SSE), which are called <em>Yin qiao san</em> and <em>Shen su yin</em> in Chinese, are commonly used herbal medicines for the common cold in East Asian countries. This study aimed to evaluate the effectiveness and safety of EKS and SSE for treating the common cold.</p></div><div><h3>Methods</h3><p>A randomized, patient-assessor-blind, placebo-controlled, parallel, and multicenter clinical trial was conducted. Adult participants who had one or more cold within 48 h before screening, were randomly allocated to EKS, SSE, or placebo groups. The recruitment goal was planned to be 375 participants. They took an EKS, SSE, or placebo, thrice daily for up to 8 days. The primary outcome was the change in the total score of the Wisconsin Upper Respiratory Symptom Scale-21-Korean version (WURSS-21-K) on day 6 compared to the baseline. The secondary outcomes included visual analog scale (VAS) scores and the duration of symptoms was assessed throughout the trial.</p></div><div><h3>Results</h3><p>A total of 128 participants were enrolled and 44, 42, and 42 were allocated to the EKS, SSE, and placebo groups, respectively. This study was prematurely terminated due to the COVID-19 pandemic, and we were unable to recruit all the planned participants (<em>n</em> = 375). EKS showed significant clinical effectiveness over the placebo group in the treatment of the common cold, as assessed by the total, symptom, and quality of life scores of WURSS-21-K and VAS, whereas SSE showed significant improvement over the placebo group in terms of WURSS-21-K symptom score. No severe adverse events were reported.</p></div><div><h3>Conclusions</h3><p>Although EKS and SSE demonstrated statistically significant clinical effectiveness and safety in patients with the common cold, we failed to recruit our pre-planned number of participants. Future definitive full-scale studies are needed to confirm these results.</p></div><div><h3>Trial registration</h3><p>ClinicalTrials. gov, registration number: NCT04073511. Registered on 29 August 2019.</p></div>","PeriodicalId":13644,"journal":{"name":"Integrative Medicine Research","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213422023000847/pdfft?md5=8952520b884b0121b0f97bd01c85f92e&pid=1-s2.0-S2213422023000847-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Integrative Medicine Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213422023000847","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Eunkyosan (EKS) and Samsoeum (SSE), which are called Yin qiao san and Shen su yin in Chinese, are commonly used herbal medicines for the common cold in East Asian countries. This study aimed to evaluate the effectiveness and safety of EKS and SSE for treating the common cold.

Methods

A randomized, patient-assessor-blind, placebo-controlled, parallel, and multicenter clinical trial was conducted. Adult participants who had one or more cold within 48 h before screening, were randomly allocated to EKS, SSE, or placebo groups. The recruitment goal was planned to be 375 participants. They took an EKS, SSE, or placebo, thrice daily for up to 8 days. The primary outcome was the change in the total score of the Wisconsin Upper Respiratory Symptom Scale-21-Korean version (WURSS-21-K) on day 6 compared to the baseline. The secondary outcomes included visual analog scale (VAS) scores and the duration of symptoms was assessed throughout the trial.

Results

A total of 128 participants were enrolled and 44, 42, and 42 were allocated to the EKS, SSE, and placebo groups, respectively. This study was prematurely terminated due to the COVID-19 pandemic, and we were unable to recruit all the planned participants (n = 375). EKS showed significant clinical effectiveness over the placebo group in the treatment of the common cold, as assessed by the total, symptom, and quality of life scores of WURSS-21-K and VAS, whereas SSE showed significant improvement over the placebo group in terms of WURSS-21-K symptom score. No severe adverse events were reported.

Conclusions

Although EKS and SSE demonstrated statistically significant clinical effectiveness and safety in patients with the common cold, we failed to recruit our pre-planned number of participants. Future definitive full-scale studies are needed to confirm these results.

Trial registration

ClinicalTrials. gov, registration number: NCT04073511. Registered on 29 August 2019.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
中药(恩教山/阴巧散和三寿心/参素饮)治疗普通感冒的疗效:一项随机、安慰剂对照、多中心临床试验
▽背景=在东亚地区,被称为“阴翘散”和“参素阴”的登教山(EKS)和三合金(SSE)是治疗感冒的常用草药。本研究旨在评价EKS和SSE治疗普通感冒的有效性和安全性。方法采用随机、患者-评估者盲、安慰剂对照、平行、多中心临床试验。筛查前48小时内发生一次或多次感冒的成年参与者被随机分配到EKS组、SSE组或安慰剂组。招募目标计划为375名参与者。他们每天服用三次EKS、SSE或安慰剂,持续8天。主要结局是第6天威斯康星上呼吸道症状量表-21-韩文版(wss -21- k)总分与基线相比的变化。次要结果包括视觉模拟量表(VAS)评分,并在整个试验期间评估症状的持续时间。结果共纳入128名受试者,分别有44名、42名和42名受试者被分配到EKS组、SSE组和安慰剂组。由于COVID-19大流行,本研究过早终止,我们无法招募到所有计划的参与者(n = 375)。通过wwurss -21- k和VAS的总评分、症状和生活质量评分来评估,EKS在治疗普通感冒方面比安慰剂组有显著的临床疗效,而SSE在wwurss -21- k症状评分方面比安慰剂组有显著的改善。无严重不良事件报告。结论:尽管EKS和SSE在普通感冒患者中具有统计学意义的临床有效性和安全性,但我们未能招募到预定数量的受试者。需要进一步的全面研究来证实这些结果。registrationClinicalTrials审判。,注册号:NCT04073511。2019年8月29日注册
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Integrative Medicine Research
Integrative Medicine Research Medicine-Complementary and Alternative Medicine
CiteScore
6.50
自引率
2.90%
发文量
65
审稿时长
12 weeks
期刊介绍: Integrative Medicine Research (IMR) is a quarterly, peer-reviewed journal focused on scientific research for integrative medicine including traditional medicine (emphasis on acupuncture and herbal medicine), complementary and alternative medicine, and systems medicine. The journal includes papers on basic research, clinical research, methodology, theory, computational analysis and modelling, topical reviews, medical history, education and policy based on physiology, pathology, diagnosis and the systems approach in the field of integrative medicine.
期刊最新文献
Editorial Board Contents Protective effect of Korean red ginseng water extract on levothyroxine-induced hyperthyroidism and propylthiouracil-induced hypothyroidism in rats An evidence map on traditional medicine across health outcomes Effectiveness and safety of Liriope Tuber (Liriopis seu Ophiopogonis Tuber, Maidong) included traditional herbal medicine for patients with paroxysmal atrial fibrillation: A systematic review, meta-analysis, and network analysis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1